Marquee Middle Image

Faculty Profile

Edward L. Schwartz, Ph.D.

Dr. Edward L. Schwartz

Professor, Department of Medicine (Oncology)

 

Professional Interests

The formation of new blood vessels (angiogenesis) is a critical process in the growth of tumors and provides a means by which they can spread to distant sites. My laboratory explores the mechanisms by which certain angiogenic factors stimulate blood vessel-forming endothelial cells, studies the molecular actions of experimental and established cancer chemotherapeutic drugs which inhibit the angiogenic process, and participates in the design and testing of new agents which could provide novel clinical approaches to inhibit angiogenesis in cancer. Among our current interests are the understanding of signal transduction pathways which mediate migration in the endothelial cell, including the formation of focal adhesions, the activation of cell surface integrins, the phosphorylation and activation of regulatory proteins, and the interaction of these components with microtubules and the cell cytoskeleton.

 

Selected Publications

Zou Y, Ling YH, Sironi, J, Schwartz EL, Perez-Soler R, Piperdi B. (2013) The autophagy inhibitor chloroquine overcomes the innate resistance to erlotinib of non-small cell lung cancer cells with wild-type EGFR. J. Thoracic Oncology, 8:693-702.

Pula G, Dunn WB, Garonna E, Watson KE, Hirano M, Pizzorno G, Schwartz EL, el Kouni MH, Wheeler-Jones CPD. (2010) Paracrine stimulation of endothelial cell motility and in vitro wound repair by platelet-derived deoxyribose-1-phosphate. Arteriosclerosis, Thrombosis, and Vascular Biology. 30:2631-8.

Lu H, Klein RS and Schwartz EL (2009) Anti-angiogenic and anti-tumor activity of a novel thymidine phosphorylase inhibitor, 6-(2-aminoethyl)amino-5-chlorouracil (AEAC), in combination with the VEGF-Trap. Clinical Cancer Research, 15: 5136-5144.

Dalyot-Herman N, Delgado-Lopez F, Gewirtz DA, Gupton JT and Schwartz EL (2009) Interference with endothelial cell function by JG-03-14, an agent that binds to the colchicine site on microtubules.  Biochemical Pharmacology 78:1167-77.

Schwartz EL (2009) Anti-vascular actions of microtubule-binding drugs.  Clinical Cancer Research 15:2594-2601.

Schwartz, EL (2008) Taxotere.  In: M. Schwab (editor) The Encyclopedia of Cancer, 2nd edition.  Springer.

Murtagh J, Lu H and Schwartz EL (2006)  Taxotere-induced inhibition of endothelial cell migration is a result of Hsp90 degradation.  Cancer Research 66:8192-8199.

Lu, H, Murtagh J and Schwartz EL (2006) The microtubule binding drug laulimalide inhibits VEGF-induced human endothelial cell migration, and is synergistic when combined with Taxotere.  Molecular Pharmacology 69:1207-1215.

Hotchkiss, KA, Ashton AW and Schwartz EL (2003) The angiogenic factors thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by activation of integrins alpha-5 beta-1 and alpha-v beta-3.  J. Biological Chemistry 278:19272-19279.

 

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Contact

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Block, Room 614
Bronx, NY 10461

Tel: 718.430.8864
Fax: 718.430.2044
edward.schwartz@einstein.yu.edu

 
Pubmed Search
Collexis Research Profiles
Einstein Research Profiles (ERP) is one of the innovative technologies to create collaborative bridges within and across the entire bench-to-bedside-to-population spectrum of research. The ERP website has been developed in partnership with Collexis to give investigators easy access to PubMed publications, coauthor networks, information about NIH grants, and research networks.